United States Health

Karyopharm Therapeutics (NASDAQ:KPTI) submitted a supplemental New Drug Application to the U.S. Food and Drug Administration seeking accelerated approval for XPOVIO (selinexor) combined with ruxolitinib to treat patients with myelofibrosis.

Eli Lilly (NYSE:LLY) reported 52-week results from the Phase 3b TOGETHER-PsO and TOGETHER-PsA trials showing Taltz (ixekizumab) plus Zepbound (tirzepatide) improved outcomes compared with Taltz alone in adults with psoriasis or psoriatic arthritis and overweight or obesity.

BioLineRx (NASDAQ:BLRX) reported second quarter 2026 results with royalty revenue of $0.3 million and a net loss of $4.3 million, compared with a net loss of $3.9 million in the prior-year period.

Lilly (NYSE:LLY) signed a definitive agreement to acquire Merida Biosciences for up to $2.875 billion in cash, adding precision biologics programs targeting autoimmune and allergic diseases.

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported second interim overall survival results from the Phase 3 HERIZON-GEA-01 trial showing Ziihera (zanidatamab-hrii) plus chemotherapy improved overall survival compared with trastuzumab plus chemotherapy in first-line HER2-positive gastroesophageal adenocarcinoma.

BeOne Medicines (NASDAQ:ONC) reported Phase 3 HERIZON-GEA-01 trial results showing ZIIHERA (zanidatamab) plus chemotherapy produced a statistically significant improvement in overall survival compared with trastuzumab plus chemotherapy in first-line treatment of HER2-positive gastroesophageal adenocarcinoma.

IDEAYA Biosciences (NASDAQ:IDYA) reported that an FDA Type C meeting provided guidance for the planned global randomized Phase 3 trial of IDE849, a DLL3-targeting TOP1 antibody-drug conjugate for extensive stage small cell lung cancer.

Alvotech (NASDAQ:ALVO) announced that the U.S. Food and Drug Administration accepted its Biologics License Application for AVT80, a proposed interchangeable biosimilar to Entyvio (vedolizumab) in prefilled syringe and autoinjector formats.

BioMarin (NASDAQ:BMRN) entered into binding global settlement terms with Ascendis Pharma A/S to resolve patent disputes involving Yuviwel, including a U.S. International Trade Commission investigation and litigation in multiple countries.

Amgen (NASDAQ:AMGN) reported Phase 3 VESALIUS-CV trial results showing Repatha reduced the risk of death by 20% among more than 12,000 high-risk adults without previous heart attack or stroke over a median 4.6-year follow-up.

Amarin (NASDAQ:AMRN) reported new post hoc REDUCE-IT Legacy analysis data showing that patients with high adherence to icosapent ethyl experienced an approximately 29%–30% relative reduction in the primary cardiovascular endpoint compared with placebo.

United Therapeutics (NASDAQ:UTHR) announced eight presentations at the 2026 European Society of Cardiology and European Respiratory Society congresses covering investigational therapies for pulmonary arterial hypertension and other lung diseases.